Personalized ADHD Medication

An Applied Research Project

Objectification of ADHD Medication

Diagnosis and therapy in today’s ADHD treatment are heavily marked by subjective elements.

Therefore, the Hirschmann Foundation aims at contributing to the objectification of diagnosis and therapy in ADHD treatment by supporting a research project conducted by the Brain and Trauma Foundation Grisons.

Testing new methods of measurement

Today’s risk of (medical) mistreatment shall be reduced through the testing of new methods of measurement and the application of biomarkers. The question of how people who suffer from ADHD can be best supported is at stake.

The research concept that has been developed by the Brain and Trauma Foundation will be realized in collaboration with the University Hospital of Psychiatry Zurich, practicing doctors, therapists, as well as computer scientists.

Detecting Interdependencies

The collected biomarker data are being put into relation with various approaches to therapy and treatment. Further, the factuality of postulated interdependencies is being examined.

Upon conclusion of the research project, the results will be made available to the interested public in a scientific publication.

The interdisciplinary research project will be funded by the Hirschmann Foundation with a contribution of CHF 0.5 mio. during a period of three years.

Partner

The Hirschmann Foundation partners with the Brain and Trauma Foundation Chur (Dr. Giusep Nay and Dr. Andreas Müller), the Department of Psychiatry, Psychotherapy, and Psychosomatics at the University Hospital of Psychiatry Zurich (Prof. Dr. med. Erich Seifritz, Director of the Department of Psychiatry, Psychotherapy, and Psychosomatics, and Prof. Dr. med. Dominique Eich-Höchli, Head of Department at the University Hospital of Psychiatry) as well as Prof. Juri Kropotov, Director of laboratory of the Institute of the Human Brain of the Russian Academy of Sciences, St. Petersburg.

Website: www.adhd-studie.ch